Nebivolol is a novel B-1-adrenoceptor-blocking drug with an unusual hemo dynamic profile unlike classical B-blockers. In dogs and in healthy volunteers it decreases blood pressure and heart rate but improves left ventricular function. The authors studied 10 male patients with coronary artery disease and heart failure (ejection fraction mean = 46%). A Swan-Ganz catheter was placed into the pulmonary artery, and the mean blood pressure, the heart rate, the pulmo nary artery pressure, the pulmonary wedge pressure, the right atrial pressure, the cardiac output, and the stroke volume were measured at rest and on exer tion before and after seven days' treatment with oral nebivolol (5 mg/day). While the blood pressure and the heart rate decreased significantly, the pulmo nary artery and wedge pressures, as well as the right atrial pressure and the cardiac output, did not change during treatment. The stroke volume increased significantly. The maintained cardiac output cannot be explained by any changes in preload or afterload; instead a positive inotropic mechanism must be assumed. Unlike other B-blockers it seems to be possible to treat patients with heart failure with nebivolol without causing the hemodynamic situation to dete riorate.
Get full access to this article
View all access options for this article.
References
1.
Pauwels P., Gommeren W., Van Lommen G, et al: The repector binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-anrenergic blockers . Mol Pharmacol34:843-851, 1988.
2.
Van de Water A., Janssens W., Van Nueten J., et al: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta-1-adrenergic antagonist. J Cardiovasc Pharmacol11:552-563, 1988.
3.
Xhonneux R., de Reese R., Van Dael L., et al: The blood pressure lowering effect of dl-Nebivolol in spontaneously hypertensive rats—the potentiating action of 1-nebivolol and d-nebivolol and some other compounds. International symposium on cardiovascular disease and beta-adrenoceptor function. Antwerp, Belgium, October 8, 1988, pp 16,17.
4.
De Crée J., Geukens H., Cobo C., et al: Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology6:440-448, 1987.
5.
Braunwald E, Sonnenblick EH, eds. Heart Failure. New York: Raven Press, 1984, pp 1-13.
6.
Alderman J., Grossman W.: Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy ?Circulation71:854-857, 1985.
7.
Shanes JG: Beta—blockade—rational or irrational therapy for congestive heart failure?Circulation76:971-973, 1987.
8.
Burkart F., Pfisterer M., Steinmann E.: Wirkungen von Bisoprolol—im Vergleich zu Metoprolol und Bufuralol—auf die linksventrikuldre Hämodynamik in Ruhe und unter Belastung bei chronischer koronarer Herzkrankheit. J Cardiovasc Pharmacol8 (Suppl 11):89-93, 1986.
9.
Stokholm KH, Lund JD, Trap-Jensen J.: Immediate haemodynamic effects of atenolol, bopindolol and placebo: a double-blind crossover study of the partial agonist activity of bopindolol. Curr Opinion Cardiol3 (Suppl 2):89-91, 1988.
10.
De Crée J.: Haemodynamic effects in man during exercise of a single oral dose of nebivolol (R 6T 555), a new beta-1-adrenoceptor blocking agent: A comparative study with atenolol, pindolol and propranolol. Drug Dev Res8:109-117, 1986.
11.
Van Bortel L. , Schiffers P., Mooy J.: Invasive hemodynamics of nebivolol in hypertensive patients. A preliminary report. International symposium on cardiovascular disease and beta-adrenoceptor function. Antwerp, Belgium, October 8, 1988, pp 46, 47.
